scholarly article | Q13442814 |
P356 | DOI | 10.3109/08916939908995386 |
P698 | PubMed publication ID | 10433078 |
P2093 | author name string | J Delgado | |
R Perez | |||
E Montero | |||
L Falcon | |||
Y Morera | |||
J F Amador | |||
P433 | issue | 2 | |
P1104 | number of pages | 2 | |
P304 | page(s) | 155-156 | |
P577 | publication date | 1999-01-01 | |
P1433 | published in | Autoimmunity | Q4826348 |
P1476 | title | CD6 molecule may be important in the pathological mechanisms of lymphocytes adhesion to human skin in psoriasis and ior t1 MAb a possible new approach to treat this disease | |
P478 | volume | 29 |
Q28295917 | A Ligand for CD5 Is CD5 |
Q37390483 | A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis |
Q88716412 | CD6 monoclonal antibodies differ in epitope, kinetics and mechanism of action |
Q38341487 | CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction |
Q34874471 | Control of advanced cancer: the road to chronicity |
Q36830250 | Genetic polymorphisms of cell adhesion molecules in Behcet's disease in a Chinese Han population |
Q51820107 | Humanization of Predicted T-Cell Epitopes Reduces the Immunogenicity of Chimeric Antibodies: New Evidence Supporting a Simple Method |
Q38730494 | Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases |
Q51075376 | Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab). |
Q48265755 | The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial. |
Q52935897 | [New developments in the systemic treatment of psoriasis]. |
Search more.